Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo.
Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients
- Thread starter Educator
- Start date